BioInvent International AB (publ) (OM: BINV)
Health Care · Biotechnology · SE
Skr24.05
-0.62% today · -36.0% 1Y
BioInvent International AB (publ) (OM: BINV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $168.17M and employs 112 people.
Over the last twelve months the share price has lost 36.0%, trading between 19.22 and 37.95.
Tweenvest scores BioInvent International AB (publ) across four factors: quality 28/100, value 59/100, growth 71/100. Its strongest factor is growth.
BINV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $168.17M
- Revenue (TTM)
- $22.89M
- P/E
- —
- EPS
- -5.10
- Dividend yield
- —
- Beta (5Y)
- 0.02
- 52-week high
- Skr37.95
- 52-week low
- Skr19.22
- Avg volume (3M)
- —
- Shares outstanding
- 65.80M
- Employees
- 112
- Next earnings
- —
About BioInvent International AB (publ)
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
- ISIN
- SE0015244520
- Founded
- 1996
- Listed since
- Jun 12, 2001
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.74 | +0.09% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.56 | +0.30% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.47 | -1.10% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.